Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02517502 · ClinicalTrials.gov registry record · Early Phase 1
Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy
A Early Phase 1 study of Cognitive Dysfunction, sponsored by Carol Fabian, MD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT02517502: Completed Early Phase 1 study of Cognitive Dysfunction, sponsored by Carol Fabian, MD.
NCT02517502 is a Early Phase 1 study of Cognitive Dysfunction that has completed, run by Carol Fabian, MD. The registered enrollment target is 24 participants, below the 1,992-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02517502, a Early Phase 1 study of Cognitive Dysfunction, has completed, sponsored by Carol Fabian, MD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if a high dose of DHA begun prior to and continued during neo-adjuvant chemotherapy (chemotherapy given prior to surgery) is likely to prevent or lessen chemotherapy induced cognitive dysfunction.
Primary Outcome
Number of potentially eligible subjects who consent to participate in the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG DHA
Study Locations (2)
Illinois
- Decatur Memorial Hospital - Decatur
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-07 |
| Est. Completion | 2019-05-03 |
| Phase | Early Phase 1 |
What the finished NCT02517502 record still lists
NCT02517502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,992-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cognitive Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02517502 reports a single indexed study location in Illinois, Kansas.
Frequently Asked Questions
What is clinical trial NCT02517502 about?
NCT02517502 is a clinical study titled "Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy". The purpose of this study is to determine if a high dose of DHA begun prior to and continued during neo-adjuvant chemotherapy (chemotherapy given prior to surgery) is likely to prevent or lessen chemotherapy induced cognitive dysfunction.
What is the current status of trial NCT02517502?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2015-07. Estimated completion is 2019-05-03.
What conditions does trial NCT02517502 study?
This clinical trial studies the following conditions: Cognitive Dysfunction.
What interventions are being tested in trial NCT02517502?
The interventions under investigation include: Placebo (DRUG), DHA (DRUG).
Who is sponsoring clinical trial NCT02517502?
This trial is sponsored by Carol Fabian, MD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02517502 being conducted?
This trial has 2 study locations across Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02517502's enrollment target sits among peer trials
24 34th of 45 higher than 9 of 45 other Cognitive Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD
COMPLETED · Early Phase 1
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Surviving Daily Life
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
RECRUITING · NA
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia